# US 2025/0082629 A1 · Antiproliferative compounds and second active agents for combined use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082629 A1
- Document ID: US20250082629A1
- Status: Published application
- Kind: A1
- Application number: 18/955,085
- Filed: 2024-11-21
- Published: 2025-03-13
- Earliest claimed: 2019-01-09
- Assignees: Celgene Corporation
- Applicants: Celgene Corporation
- Inventors: Lilly L. Wong
- Web page: https://patentgrep.com/patent/US20250082629A1

## CPC

- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4523: containing further heterocyclic ring systems
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 31/497: containing further heterocyclic rings
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/69: Boron compounds
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma. The second active agent is one or more of a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an MEK inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BRD4 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a BIRC5 inhibitor, a BET inhibitor, or a DNA methyltransferase inhibitor.

## Claims

### Claim 1

A method of treating multiple myeloma comprising administering to a patient in need thereof a therapeutically effective amount of a compound in combination with a second active agent, wherein the compound is Compound 1 of formula
or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof; and wherein the second active agent is one or more of a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an MEK inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BRD4 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a BIRC5 inhibitor, a BET inhibitor, or a DNA methyltransferase inhibitor.

### Claim 2

A method of treating multiple myeloma comprising administering to a patient in need thereof a therapeutically effective amount of a compound in combination with a second active agent, wherein the compound is Compound 2 of formula
or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof; and wherein the second active agent is one or more of a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an MEK inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BRD4 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a BIRC5 inhibitor, a BET inhibitor, or a DNA methyltransferase inhibitor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the compound is Compound 2.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a BTK inhibitor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the BTK inhibitor is ibrutinib, or acalabrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the BTK inhibitor is ibrutinib.

### Claim 7 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is an mTOR inhibitor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mTOR inhibitor is rapamycin or an analog thereof (also termed rapalog).

### Claim 9 (depends on 8)

The method of claim 8, wherein the mTOR inhibitor is everolimus.

### Claim 10 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a PIM inhibitor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the PIM inhibitor is LGH-447, AZD1208, SGI-1776, or TP-3654, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the PIM inhibitor is LGH-447 or a hydrochloride salt of LGH-447.

### Claim 13 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is an IGF-1R inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the IGF-1R inhibitor is linsitinib.

### Claim 15 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is an MEK inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the MEK inhibitor is trametinib, trametinib dimethyl sulfoxide, cobimetinib, binimetinib, or selumetinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the MEK inhibitor is trametinib or trametinib dimethyl sulfoxide.

### Claim 18 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is an XPO1 inhibitor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the XPO1 inhibitor is selinexor.

### Claim 20 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a DOT1L inhibitor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the DOT1L inhibitor is SGC0946, or pinometostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the DOT1L inhibitor is SGC0946.

### Claim 23 (depends on 21)

The method of claim 21, wherein the DOT1L inhibitor is pinometostat.

### Claim 24 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is an EZH2 inhibitor.

### Claim 25 (depends on 24)

The method of claim 24, wherein the EZH2 inhibitor is tazemetostat, 3-deazaneplanocin A (DZNep), EPZ005687, EI1, GSK126, UNC1999, CPI-1205, or sinefungin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the EZH2 inhibitor is tazemetostat.

### Claim 27 (depends on 25)

The method of claim 25, wherein the EZH2 inhibitor is UNC1999.

### Claim 28 (depends on 25)

The method of claim 25, wherein the EZH2 inhibitor is CPI-1205.

### Claim 29 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a JAK2 inhibitor.

### Claim 30 (depends on 29)

The method of claim 29, wherein the JAK2 inhibitor is fedratinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, momelotinib, or pacritinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 30)

The method of claim 30, wherein the JAK2 inhibitor is fedratinib.

### Claim 32 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a BRD4 inhibitor.

### Claim 33 (depends on 32)

The method of claim 32, wherein the BRD4 inhibitor is JQ1.

### Claim 34 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a PLK1 inhibitor.

### Claim 35 (depends on 34)

The method of claim 34, wherein the PLK1 inhibitor is BI2536.

### Claim 36 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is an NEK2 inhibitor.

### Claim 37 (depends on 36)

The method of claim 36, wherein the NEK2 inhibitor is JH295.

### Claim 38 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is an AURKB inhibitor.

### Claim 39 (depends on 38)

The method of claim 38, wherein the AURKB inhibitor is barasertib or AZD1152-HQPA.

### Claim 40 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a BIRC5 inhibitor.

### Claim 41 (depends on 40)

The method of claim 40, wherein the BIRC5 inhibitor is YM155.

### Claim 42 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a BET inhibitor.

### Claim 43 (depends on 42)

The method of claim 42, wherein the BET inhibitor is birabresib or Compound C (4-[2-(cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1 (2H)-one), or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the second active agent is a DNA methyltransferase inhibitor.

### Claim 45 (depends on 44)

The method of claim 44, wherein the DNA methyltransferase inhibitor is azacitidine.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 1 to 45, wherein the multiple myeloma is relapsed, refractory or resistant.

### Claim 47 (depends on 46)

The method of claim 46, wherein the multiple myeloma is refractory or resistant to lenalidomide.

### Claim 48 (depends on 46)

The method of claim 46, wherein the multiple myeloma is refractory or resistant to pomalidomide.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 1 to 45, wherein the multiple myeloma is newly diagnosed multiple myeloma.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 1 to 49, additionally comprising administering to the patient an additional active agent.

### Claim 51 (depends on 50)

The method of claim 50, wherein the additional active agent is dexamethasone.

### Claim 52 (depends on 50)

The method of claim 50, wherein the additional active agent is bortezomib.
